Goals: To characterize the epidemiology of opioid-related visits to United States (US) emergency departments (EDs) and describe trends in opioid-related visits over time.
Design: Retrospective cohort study CASES: The National Hospital Ambulatory Care Survey (NHAMCS) was used to identify opioid-related ED visits between 1999 and 2013.
Measurements: The NHAMCS is an annual, weighted, multi-stage survey which allows for the study of ambulatory care services within a nationally representative sample of US hospitals. We used ICD-9 codes to identify ED visits related to opioid use and abuse. We applied visit weights calculated by NHAMCS to generate nation-wide estimates regarding the overall prevalence of opioid-related visits, and demographic characteristics of these patients. We report trends with respect to opioid-related visits and ED resource utilization between 1999 and 2013.
Results: 1072 visits were included, representing 2,731,000 nation-wide opioid-related ED encounters between 1999 and 2013. During this time, opioid-related ED visits increased from 125,000 in 1999 to over 300,000 visits in 2013. Between 1999-2001 and 2011-2013 opioid-related visits increased by 170%. Greater numbers of such visits occurred across nearly all demographic groups, and all regions of the US. Weighted visits among women increased by 250% between these time periods. Over these periods, opioid-related ED visits resulting in hospital admission increased by over 240%. The proportion of ED visits that were related to opioids doubled from 1999 (0.12%) to 2013 (0.25%).
Conclusions: Opioid-related ED encounters and resource utilization both rose substantially between 1999 and 2013, with consistent increases across a broad spectrum of demographic groups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajem.2019.03.052 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of Preemptive Genotyping in Cancer Palliative Care.
J Pain Res
December 2024
Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL, USA.
Background: Cancer patients frequently suffer from pain, often managed with opioids. However, undertreated pain remains a significant concern. Opioid effectiveness varies due to genetic differences in how individuals metabolize some of these medications.
View Article and Find Full Text PDFThe contribution of nonmedical opioid use to healthcare encounters for opioid overdose and use disorders among long-term users with metastatic cancer.
Support Care Cancer
December 2024
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, 2500 University Drive NW, Calgary, AB, T2N 1N4, Canada.
Purpose: Opioid misuse is increasingly recognized as a relevant problem among patients with cancer. However, the applicability of these concerns for patients with metastatic disease is complicated by shorter prognoses and greater symptom burden. This study aimed to investigate whether nonmedical opioid use (NMOU) was identified as contributing to opioid-related healthcare encounters among patients with metastatic cancer receiving long-term prescribing.
View Article and Find Full Text PDFPatient and provider experiences with opioid use disorder care delivered via telehealth: A systematic mixed-studies review.
Drug Alcohol Depend
January 2025
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Introduction: Since the onset of the COVID-19 pandemic and loosening of some opioid use disorder (OUD) treatment regulations in the U.S. and Canada, there has been a rapid rise in the use of telehealth for buprenorphine induction, maintenance, and counseling (tele-bupe).
View Article and Find Full Text PDFDoor-to-door overdose harm reduction: an Illinois case study.
Harm Reduct J
December 2024
Buehler Center for Health Policy and Economics, Institute for Public Health and Medicine, Northwestern University, 420 E. Superior St. 9th Floor, Chicago, IL, 60611, USA.
Article Synopsis
- Harm reduction for people who use drugs (PWUD) is a key strategy in US drug policy, focusing on meeting communities’ needs and providing various support services.
- The Block-by-Block (BXB) intervention, launched in 2022 across five pilot areas in Illinois, aims to distribute naloxone and drug test strips in private or neutral settings to reduce opioid-related fatalities.
- Early results show that the BXB initiative is feasible, with a 55% response rate at homes approached, and high acceptability, as 75% of those who answered were supportive of the intervention.
Impact of COVID-19 Pandemic on Emergency Department Visits for Opioid Use Disorder Across University of California Health Centers.
West J Emerg Med
November 2024
Chapman University, School of Pharmacy, Irvine, California.
Introduction: Coronavirus 2019 (COVID-19) has had a devastating impact on mental health and access to addiction treatment in the United States, including in California, which resulted in the highest rates of emergency department visits (ED) for opioid poisoning in 2020. As California slowly returns to pre-pandemic normalcy, it remains uncertain whether the rates of opioid-related events have slowed down over time. We hypothesized that the number of opioid-related ED visits were exacerbated after the period of the COVID-19 pandemic and continue at a high rate in the present.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!